|
PrognostiX, Inc. is a next generation reference laboratory focused
on proprietary esoteric tests. Our testing is based on intellectual property
which helps physicians address unmet clinical needs in major disease areas including
cardiovascular, cancer, respiratory, neurodegenerative disease and obesity.
We are developing new and innovative diagnostic and prognostic assays that enhance
and improve medical care.
PrognostiX is marketing the CardioMPO™ ELISA based test kit for in vitro diagnostic
use. The CardioMPO™ Test measures myeloperoxidase (MPO) levels in human
plasma and is intended for use as an aid in evaluating patients presenting with
chest pain that are at risk for major adverse cardiac events (MACE), including myocardial
infarction, need for revascularization, or death. The CardioMPO™ test
kits are currently available and testing is available through our CLIA-certified
reference lab.
PrognostiX has several additional key products in the pipeline, like CardioMPO™,
are based on inflammatory biomarkers. PrognostiX’ next product is a biomarker which has been shown to assist physicians in
the diagnosis and monitoring of asthma. For more information on this assay
or others in our product pipeline click here.
In addition, our Mass Spectrometry Service Group offers customized analytical support
services for clinical studies to pharmaceutical companies, government agencies and
academic institutions. Click here for
assays available through our Mass Spectrometry Lab.
|
|
PrognostiX is marketing the CardioMPO™ ELISA based
test kit for in vitro diagnostic use. The CardioMPO™ Test measures myeloperoxidase
(MPO) levels in human plasma more...
|